Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab SC in MET Amplification-Positive Stage IV or Recurrent NSCLC (LUNG-MAP SUB-STUDY)
NCT06116682Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Primary endpoint: Objective Response Rate up to 3 years. Started Nov 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06116682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116682.